Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a death receptor binding ligand, has been a highly studied drug because of its ability to selectively target cancer cells and not most normal cells [5,6]. Here, TNFSF10 is linked to cancer.